Key Points
- Josef Parvizi sold 25,000 shares of CeriBell on January 15 at an average price of $22.94 for $573,500, leaving him with 747,652 shares (a 3.24% reduction in ownership).
- That sale follows two prior disposals — 25,000 shares on December 15 at $21.49 and 25,000 on December 8 at $20.26 — totaling 75,000 shares sold in the past month-long period.
- CeriBell has a market cap of about $795.7M, a 52-week range of $10.01–$26.04 and negative EPS/margins, while analysts hold a consensus "Moderate Buy" rating with an average price target of $24.67.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Josef Parvizi sold 25,000 shares of CeriBell stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $22.94, for a total value of $573,500.00. Following the completion of the sale, the director owned 747,652 shares of the company's stock, valued at approximately $17,151,136.88. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Josef Parvizi also recently made the following trade(s):
- On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $21.49, for a total transaction of $537,250.00.
- On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total value of $506,500.00.
CeriBell Price Performance
Shares of NASDAQ:CBLL opened at $21.45 on Wednesday. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $26.04. The stock's 50 day moving average is $19.53 and its 200-day moving average is $15.23. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $795.71 million, a price-to-earnings ratio of -14.21 and a beta of 1.02.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The business had revenue of $22.59 million during the quarter, compared to analyst estimates of $21.78 million. Sell-side analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.
Institutional Trading of CeriBell
Several hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC bought a new position in shares of CeriBell during the 2nd quarter worth $1,054,000. Geode Capital Management LLC lifted its holdings in CeriBell by 55.4% during the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company's stock valued at $8,391,000 after purchasing an additional 159,698 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its stake in shares of CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company's stock worth $106,000 after purchasing an additional 3,502 shares in the last quarter. F m Investments LLC bought a new stake in shares of CeriBell in the second quarter valued at approximately $381,000. Finally, Peregrine Capital Management LLC lifted its stake in shares of CeriBell by 7.7% during the 3rd quarter. Peregrine Capital Management LLC now owns 367,945 shares of the company's stock valued at $4,228,000 after buying an additional 26,286 shares in the last quarter.
Wall Street Analyst Weigh In
A number of research firms have issued reports on CBLL. Canaccord Genuity Group lifted their price target on CeriBell from $29.00 to $30.00 and gave the company a "buy" rating in a research note on Wednesday, December 17th. Weiss Ratings reiterated a "sell (e+)" rating on shares of CeriBell in a report on Wednesday, October 8th. Raymond James Financial began coverage on CeriBell in a research note on Tuesday, October 21st. They set a "strong-buy" rating and a $19.00 price objective on the stock. BTIG Research reaffirmed a "buy" rating and set a $30.00 price objective on shares of CeriBell in a report on Monday, December 15th. Finally, JPMorgan Chase & Co. lowered their target price on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating for the company in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, CeriBell has a consensus rating of "Moderate Buy" and an average price target of $24.67.
Read Our Latest Stock Analysis on CBLL
About CeriBell
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
